10-Q: Forte Biosciences Q1 2026: Increased R&D, Cash Burn Continues

Forte Biosciences reported a net loss of $22.1 million for Q1 2026, with research and development expenses significantly increasing, while cash reserves remain substantial following a recent public offering.

Summary

• Forte Biosciences reported a net loss of $22.1 million for the first quarter ended March 31, 2026, compared to a loss of $15.7 million in the same period of 2025.
• Total operating expenses increased to $22.4 million from $16.1 million year-over-year, primarily driven by higher research and development (R&D) costs.
• R&D expenses rose to $20.5 million from $12.7 million, attributed to increased clinical trial costs for FB102 in celiac disease, vitiligo, and alopecia areata, as well as higher personnel expenses.
• General and administrative (G&A) expenses decreased to $2.0 million from $3.4 million, largely due to a legal settlement payment received.
• The company had $58.2 million in cash and cash equivalents as of March 31, 2026.
• Forte believes its current cash position, bolstered by the April 2026 public offering, is sufficient to fund operations for at least twelve months.
• The company continues to advance its lead product candidate, FB102, through various clinical trial stages for autoimmune and autoimmune-related diseases.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed sentiment. While the company secured significant funding and advanced its clinical programs with positive early data, the increased net loss and continued high cash burn are concerning. The reliance on future financing introduces substantial risk.

Positives

• Positive data from the celiac disease Phase 1b study for FB102 was announced in June 2025, showing statistically significant benefits on histological endpoints and a 42% benefit in gluten challenge induced GI symptoms compared to placebo.
• The company successfully closed a public offering on April 8, 2026, raising $172.5 million in gross proceeds, significantly bolstering its cash reserves.
• Forte believes its cash and cash equivalents, combined with the proceeds from the recent offering, are sufficient to fund operations for at least twelve months from the filing date.
• The company initiated a Phase 2 celiac study in July 2025, with topline readout expected in 2026, and the US FDA approved an IND application for a US arm of this study in November 2025.
• The Phase 1b non-segmental vitiligo trial continues enrollment with topline data expected in the first half of 2026, and a Phase 1b alopecia areata study has been initiated with topline data expected in 2026.
• The company regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.

Negatives

• The company reported a net loss of $22.1 million for the quarter, an increase from $15.7 million in the prior year's quarter.
• Research and development expenses increased significantly by $7.7 million to $20.5 million, indicating a substantial increase in cash burn.
• The company has incurred net losses in every year since its inception and anticipates continued losses in the foreseeable future.
• Forte requires significant additional capital to fund its operations and future development activities, with no assurance that such funding will be available on acceptable terms.
• The company's business is heavily dependent on the success of its single lead product candidate, FB102, which may not be successful.
• Cash and cash equivalents decreased from $76.9 million at the end of 2025 to $58.2 million at the end of Q1 2026.

Risks

• Forte will require significant additional capital to fund its operations, and failure to obtain necessary financing could prevent it from advancing or completing the clinical development and commercialization of FB102.
• The company's business is almost entirely dependent on the success of developing FB102, which may not be successful.
• Results from early preclinical studies and clinical trials may not be predictive of results from later-stage studies or clinical trials.
• Forte has no approved products and a limited operating history, making it difficult to evaluate its technology and predict future performance.
• Clinical development is a lengthy, expensive, and uncertain process, and Forte may incur additional costs or experience delays, or be unable to complete development and commercialization.
• Planned preclinical studies, clinical trials, or those of its future collaborators may reveal significant adverse events, potentially inhibiting regulatory approval or market acceptance.
• The market opportunities for FB102 may be limited, and estimates of target patient populations may be inaccurate.
• Forte expects to rely on third parties to conduct its preclinical studies and clinical trials and to manufacture its product candidates, which introduces risks related to their performance and compliance.
• The market price of Forte's common stock is expected to be volatile, and past volatility has led to securities litigation.
• The company's ability to continue as a going concern is dependent on its ability to secure future financing.
• Macroeconomic factors such as military conflicts, economic uncertainty, inflation, rising interest rates, and potential financial institution failures could impact the company's business and operations.

Future Outlook

The company believes its current cash and cash equivalents, along with the proceeds from the recent 2026 Offering, will be sufficient to fund operations for at least twelve months. However, significant additional funding will be required in the future to continue research and development, pursue regulatory activities, and commercialize product candidates. Management may seek funding through equity and debt financings or strategic partnerships. There is no assurance that additional funding will be available on acceptable terms.

Management Comments

• The Company believes that its existing cash and cash equivalents and net proceeds from the 2026 Offering will be sufficient to allow the Company to fund its operations for at least twelve months from the filing date of this Form 10-Q.
• The Company will need to secure significant additional funding in the future in order to carry out all of the Company's planned research and development activities and regulatory activities, conduct any substantial additional development requirements requested by the U.S. Food and Drug Administration ("FDA"), and commercialize product candidates.
• Management may fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources.
• There are numerous risks and uncertainties associated with pharmaceutical development and the Company is unable to predict the timing or amount of increased expenses on the development of future product candidates or when or if it will start to generate revenues.

Industry Context

StockSavvy.ai notes that Forte Biosciences operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on clinical-stage development. The company's strategy hinges on the success of FB102, a therapeutic candidate for autoimmune diseases. The significant increase in R&D spending aligns with industry norms for companies advancing drug candidates through clinical trials, while the substantial cash reserves from recent offerings provide a crucial runway for continued development.

Comparison to Industry Standards

• The net loss of $22.1 million for the quarter is substantial, reflecting the high costs associated with clinical-stage drug development, a common characteristic among biopharmaceutical companies at this stage.
• The increase in R&D expenses to $20.5 million is consistent with companies advancing multiple clinical trials, such as those Forte is conducting for FB102 in celiac disease, vitiligo, and alopecia areata.
• The company's cash burn rate, indicated by the net cash used in operating activities of $18.8 million for the quarter, is significant but is being managed through substantial capital raises, a typical financing strategy in the biotech industry.
• The market size estimates for vitiligo ($1.6-1.8 billion in 2024-2025, projected to $2.3-2.7 billion by 2032-2034) and alopecia areata ($3-3.5 billion in 2024, projected to $6 billion by 2032-2034) indicate substantial potential markets, aligning with industry trends for treatments addressing unmet medical needs in dermatology and immunology.
• The company's reliance on third-party CROs and CMOs for clinical trials and manufacturing is standard practice in the biopharmaceutical industry, though it introduces risks related to control and timelines.

Legal Proceedings

• Forte Biosciences filed a complaint against its Directors & Officers liability insurance providers (Wesco Insurance Company, Beazley Insurance Company, and Palms Insurance Company) for refusal to cover obligations related to the Camac Fund, LP v. Paul A. Wagner, et al. action. The Delaware Superior Court ruled in favor of Forte, finding Wesco and Palms liable up to their policy limits. Palms paid $2.3 million as an interim payment, and Wesco paid $2.5 million plus prejudgment interest under a confidential settlement.

Related Party Transactions

• One member of the Company's board of directors received $150,000 each quarter for scientific and clinical consulting services during the three months ended March 31, 2026 and 2025.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, volatility in stock price, but also potential upside if FB102 is successful. The company's ability to continue as a going concern depends on future financing.
• Employees: Continued employment dependent on company's financial health and success of FB102. Stock-based compensation remains a significant component of employee incentives.
• Creditors: The company's significant cash reserves and recent capital raises provide a buffer, but future financing needs could impact debt covenants if debt financing is pursued.
• Suppliers/Vendors: Continued business dependent on the company's operational continuity and ability to meet payment obligations, which are supported by current cash reserves.

Next Steps

• Continue advancing FB102 through clinical trials for celiac disease (Phase 2), non-segmental vitiligo (Phase 1b), and alopecia areata (Phase 1b).
• Expect topline readout for the Phase 2 celiac study in 2026.
• Expect topline data for the Phase 1b non-segmental vitiligo trial in the first half of 2026.
• Expect topline data for the Phase 1b alopecia areata study in 2026.
• Continue to monitor and manage cash burn and seek future funding as needed.
• Potentially pursue additional autoimmune indications for FB102.

Key Dates

Recommendation

Forte Biosciences presents a high-risk, high-reward profile typical of clinical-stage biotechs. The positive Phase 1b data for FB102 in celiac disease and the substantial capital raised are significant positives. However, the increased net loss, substantial cash burn, and the critical need for future financing to advance FB102 through later-stage trials introduce considerable risk. The company's success is heavily reliant on a single product candidate. Given the uncertainties and the need for further clinical validation, a 'hold' recommendation is appropriate, suggesting investors monitor clinical trial progress and financing developments closely.

Keywords

Forte Biosciences, 10-Q, Quarterly Report, FB102, Biopharmaceutical, Autoimmune Diseases, Celiac Disease, Vitiligo, Alopecia Areata, Clinical Trials, R&D Expenses, Net Loss, Cash Burn, Public Offering, SEC Filing